hif1-β)

Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.

Acetylarenobufagin is a steroidal hypoxia-inducible factor-1 (HIF-1) modulator.

GN44028 (N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1,4-dihydroindeno[1,2-c]pyrazol-3-amine) is a hypoxia-inducible factor inhibitor of (HIF)-1 (IC50: 14 nM). GN44028 inhibits hypoxia-induced HIF-1α transcriptional activity. However, It can not be suppressing HIF-1α mRNA expression, HIF-1α protein accumulation, or HIF-1α/HIF-1β heterodimerization.

Cucurbitacin B (Cuc B) has profound in vitro and in vivo antiproliferative effects against human pancreatic Y cells. It inhibited AKT signaling activation through up-regulation of PTEN. Cucurbitacin B is an effective inhibitor of HIF-1 and provide new perspectives into the mechanism of its anticancer activity. Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung Y cells.

LW6 (HIF-1α inhibitor) is a novel HIF-1 inhibitor.

HIF-1 inhibitor-4 (HIF-1 inhibitor-4) is a HIF-1 inhibitor with IC50 of 560 nM. HIF-1 inhibitor-4 reduces the HIF-1α protein level without affecting its mRNA level.

Chetomin (BRN0077366) is an inhibitor of HIF-1 by weaken transcription of HIF-1, disrupting the binding of HIF-1α and HIF-2α to p300 at low nanomolar concentrations.

HIF1-IN-3 (Benzenepropanamide, N-[(8-hydroxy-7-quinolinyl)(4-methoxyphenyl)methyl]-) is an effective inhibitor of HIF-1 (EC50 = 0.9 μM) and can be used in anticancer studies.

Cephaeline was highly active against protected primary CLL cells (relative IC50's 35nM ) and acted by repressing HIF-1α± and disturbing intracellular redox homeostasis.

Cyclo CRLLIF serves as a dual inhibitor of hypoxia-inducible factors HIF1 and HIF2, disrupting the interaction between HIF1-α and HIF2-α with HIF1-β. It exhibits dissociation constants (KD) of 14.5 μM for HIF1-α and 10.2 μM for HIF2-α within the PAS-B domains.

Cyclo CRVIIF is a dual inhibitor of hypoxia-inducible factors HIF1 and HIF2. It disrupts the interaction between HIF1-α, HIF2-α, and HIF1-β, with dissociation constants (KD) for the PAS-B domains of HIF1-α and HIF2-α measured at 65 and 123 μM, respectively.

Cyclo CKLIIF is a dual inhibitor of the hypoxia-inducible factors HIF1 and HIF2, effectively disrupting the interaction between HIF1-α and HIF2-α with HIF1-β. The dissociation constants (KD) for the PAS-B domains of HIF1-α and HIF2-α are 2.6 μM and 2.2 μM, respectively.